RAPA-201 is under clinical development by Rapa Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how RAPA-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RAPA-201 overview
RAPA-201 is under development for the treatment of relapsed and refractory multiple myeloma, solid tumor, gastric cancer, head and neck cancer, carcinoma of unknown primary, bladder cancer, non-small cell lung cancer, small-cell lung cancer, triple-negative breast cancer (TNBC), adenocarcinoma of the gastroesophageal junction, oral cavity (mouth) cancer, laryngeal cancer, nasopharyngeal cancer, melanoma and esophageal squamous cell carcinoma. The therapy comprises of autologous rapamycin-resistant T cells. It is administered through parenteral route.
Rapa Therapeutics overview
Rapa Therapeutics is a pharmaceutical and healthcare company. The company provides therapies for oncology disease. Rapa Therapeutics is headquartered in Rockville, Maryland, the US.
For a complete picture of RAPA-201’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
